Zai Lab (NASDAQ:ZLAB) Given a $46.00 Price Target by Leerink Swann Analysts
Zai Lab (NASDAQ:ZLAB) has been given a $46.00 price objective by Leerink Swann in a research note issued on Tuesday, Stock Target Advisor reports. The firm currently has a “buy” rating on the stock. Leerink Swann’s price target indicates a potential upside of 52.87% from the stock’s previous close.
A number of other analysts also recently issued reports on ZLAB. BidaskClub upgraded shares of Zai Lab from a “hold” rating to a “buy” rating in a report on Thursday, March 21st. Zacks Investment Research downgraded shares of Zai Lab from a “hold” rating to a “sell” rating in a report on Saturday, April 20th. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $36.90.
ZLAB opened at $30.09 on Tuesday. Zai Lab has a fifty-two week low of $14.29 and a fifty-two week high of $33.86. The firm has a market cap of $1.74 billion, a P/E ratio of -11.40 and a beta of 0.96.
Zai Lab Company Profile
Zai Lab Limited, a biopharmaceutical company, engages in discovering or licensing, developing, and commercializing proprietary therapeutics that address medical needs in the fields of oncology, and autoimmune and infectious disease therapies in the People's Republic of China. Its drug candidates include ZL-2306, a poly ADP ribose polymerase 1/2 inhibitor, which is in Phase III clinical trial for the treatment of ovarian, lung, and breast cancers; ZL-2401, an antibiotic that is in Phase III clinical trial to treat ABSSSI, CABP, and UTI; FPA144, a humanized monoclonal antibody, which is in Phase I/III clinical trial to treat gastric and gastroesophageal cancer; ETX2514, a novel ß-lactamase inhibitor that is in Phase II cUTI trial for the treatment of acinetobacter baumannii; and ZL-2301, which is in Phase III clinical trial to treat HCC.
Featured Story: Stock Split
Receive News & Ratings for Zai Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zai Lab and related companies with MarketBeat.com's FREE daily email newsletter.